Tharabiopharma Inc.
Tharabiopharma Inc., commonly referred to as Tharabiopharma, is a leading biopharmaceutical company headquartered in Japan (JP). Established in 2005, the company has made significant strides in the development of innovative therapies, focusing primarily on oncology and rare diseases. With a strong presence in both domestic and international markets, Tharabiopharma is recognised for its commitment to advancing healthcare through cutting-edge research and development. The company’s core offerings include a range of biologics and small molecule drugs, distinguished by their unique mechanisms of action and patient-centric design. Tharabiopharma has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a key player in the biopharmaceutical industry, Tharabiopharma continues to drive progress in therapeutic solutions, aiming to improve patient outcomes globally.
DitchCarbon Score
How does Tharabiopharma Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Food Product Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tharabiopharma Inc.'s score of 3 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Tharabiopharma Inc.'s reported carbon emissions
Tharabiopharma Inc., headquartered in JP, currently does not have available carbon emissions data for recent years, as indicated by the absence of specific figures. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of data suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the pharmaceutical industry, it is increasingly important for companies to establish clear climate commitments and reduction targets to align with global sustainability goals. As Tharabiopharma Inc. moves forward, it may benefit from adopting industry-standard practices, such as setting Science-Based Targets Initiative (SBTi) targets, to effectively manage and reduce its carbon footprint.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tharabiopharma Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
